Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection
Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
Two different dosing regimens demonstrated efficacy with one showing a better profile
The collaboration aims to secure manufacturing and testing capacity in the next phase of the pandemic
As SARS-CoV-2 vaccines become available, Siemens Healthineers is ready with fully automated antibody tests that can be used to help inform whether broad vaccination programs are working
Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing
Join scientists from across the globe to explore the latest developments in biopharma, from new research techniques to cutting-edge technologies and resources to advance your work
QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes
Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide
Exclusive interviews, free downloads, the latest methods and much more to help support your immuno-oncology research
The kit promises to be a low cost, high-sensitivity diagnostic test for COVID-19 detection
The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR
Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development
Discover the importance of high-throughput and robust methodologies for finding ‘needle-in-the-haystack’ therapeutic antibodies
Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
Party during Neuroscience 2018 celebrates the importance of effective conversation between scientists and manufacturers
Discover how AFABILITY founder Dr. Alison Gray is enabling the transition from animal-derived to non-animal-derived antibodies
The StarBright Blue 700, StarBright Violet 440 and StarBright Violet 610 dyes aim to offer maximal brightness for improved resolution
The platform can directly isolate IgG genes from B cells of immunized animals
Company’s latest test enables differential diagnosis between COVID-19, flu and RSV infection
Which new products made the most difference to your lab work this year?
The study leverages the Tapestri Platform to illustrate the single-cell atlas of acute myeloid leukemia (AML) with multi-omics, describing the clonality underlying therapeutic resistance
Veklury is first FDA-approved treatment for COVID-19 in the US, and aims to shorten time to recovery by five days
